The first-ever RCT on children with cystic fibrosis has discovered that treating with inhaled hypertonic saline can enhance lung health and breathing. Earlier studies utilizing mice models divulged that hypertonic saline decreased the development of the perilous mucus plugs that take place in cystic fibrosis (CF). These plugs obstruct the airways and lead to persistent chest infections.
The existing study’s lead author, Dr Mirjam Stahl, said, “CF lung disease initiates in the initial months of life, making only a narrow opportunity window available for precautionary therapeutic interventions.” One of the major factors accountable for symptomatic illness and demise in these patients is lung disease. Being able to avert it, or at least setback the onset age, or decelerate its development can be a great step forward in cystic fibrosis treatment.
The existing study demonstrated the potential to achieve this securely in the early days of life. The hypertonic saline group, at the conclusion of the 12-month follow-up duration, demonstrated a higher lung clearance index. Also, this group put on considerably more weight together with around an inch in height.
The rise in weight confirmed previous mouse CF studies that utilized hypertonic saline. A little difference was observed in both groups in the rate at which adverse events or exacerbations took place.
As per another study, a new triple-combination drug therapy being examined at the Mater Hospital in Brisbane can enhance the patient’s life expectancy having cystic fibrosis. Scientists from the Mater Research Institute-University of Queensland conducted the clinical trial focusing to treat the fundamental basis of cystic fibrosis.
The researchers said, “A new drug, called VX-445, in mixture with 2 prevailing therapies, has shown lung function improvement of about 10%—which is actually major for patients with cystic fibrosis. Individuals in our trial had a noteworthy enhancement in their lung function that they had not been capable of achieving earlier.”